Replies to post #10403 on Biotech Values

[DewDiligence]

You’re correct that the companies have never disclosed that AAB-001 is the second antibody collaboration, but there aren’t any other ELN antibodies that fit the bill.

I assume that the AAB-001 project is still viable, but confirmation from the company would be helpful.